Aequus Pharmaceuticals (TSE:AQS) has released an update.
Aequus Pharmaceuticals Inc. reports a reduced operating loss and a decline in overall revenue in Q1 2024, largely due to halting Evolve product sales, despite the launch of the new ZIMED® PF ophthalmic solution. The company has seen a decrease in expenses and is implementing marketing strategies to boost ZIMED® PF demand after its initial adoption met expectations. Meanwhile, research and development costs dropped to zero with the completed approval process for ZIMED® PF.
For further insights into TSE:AQS stock, check out TipRanks’ Stock Analysis page.
